Cite
Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints.
MLA
Halappanavar, Sabina, et al. “Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints.” Small (Weinheim an Der Bergstrasse, Germany), vol. 17, no. 15, Apr. 2021, p. e2007628. EBSCOhost, https://doi.org/10.1002/smll.202007628.
APA
Halappanavar, S., Nymark, P., Krug, H. F., Clift, M. J. D., Rothen-Rutishauser, B., & Vogel, U. (2021). Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints. Small (Weinheim an Der Bergstrasse, Germany), 17(15), e2007628. https://doi.org/10.1002/smll.202007628
Chicago
Halappanavar, Sabina, Penny Nymark, Harald F Krug, Martin J D Clift, Barbara Rothen-Rutishauser, and Ulla Vogel. 2021. “Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints.” Small (Weinheim an Der Bergstrasse, Germany) 17 (15): e2007628. doi:10.1002/smll.202007628.